Moreover, future investigation of novel coating and delivery systems that offer specifically targeting STAT3 in CD4+ T cells and/or APCs may significantly improve the benefit/risk ratio by increasing therapeutic efficacy while avoiding AEs, with the ultimate goal of treating patients with established MS. Here, CD4 is linked to myeloid sarcoma.